|Cytomedix Says Acquisition Expands Its Commitment to Regenerative Medicine|
Cytomedix Inc. a developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis based in Gaithersburg, Maryland, US, has acquired Aldagen Inc., a privately held biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell technology. The finalization of the acquisition was announced Feb. 8.
The move is part of Cytomedix's plan to expand from a wound-care based technology platform into a broader regenerative medicine company. Adding Aldagen's patent-protected cell selection technology to the company's product lineup fits well with its existing commercial products and strengthens its long-range growth profile, Cytomedix CEO Martin P. Rosendale said. "In combination, we now touch the three pillars of regenerative medicine with autologous stem cells, platelet-derived signal molecules and plasma scaffolds," he added.
Aldagen, based in Durham, North Carolina, US, is a clinical-stage biopharmaceutical company developing patent-protected autologous cell-based therapeutics for tissue repair and regeneration. Its initial focus is on developing product candidates to address cardiovascular disease.
According to the company, it has the only stem cell selection technology utilizing an intracellular enzyme marker to fractionate essential regenerative cells from bone marrow.